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RESULTS: A total of 1185 established T2DM patients were assessed. Themean (SD)
age was 55 (10) years andmean duration of diabetes (SD) of 10 (7) years. Metformin
was themost commonly prescribed drug [827 (70%)], in general followed by insulin
[627 (53%)], sulfonylureas [520 (44%)], and pioglitazone [329 (28%)]. A total of 348
(29%) patients receivedmonotherapy and 837 (71%) received combination therapy.
The most frequently prescribed monotherapy was insulin [214 (62%)], followed by
metformin in 81 (23%), sulfonylurea in 49 (14%) and pioglitazone in 4 (1%) patients.
Family history(OR 1.76, 95%CI 1.18, 2.64), diabetes duration (OR 2.62, 95% CI 2.05,
3.36), HbA1c (OR 1.25, 95%CI 1.01, 1.50), neuropathy(OR 1.57, 95% CI, 1.14, 2.2), ne-
phropathy(OR 1.77, 95% CI 1.40, 2.24), retinopathy (OR 1.97, 95% CI 1.63, 2.40), Cor-
onary Artery Disease (CAD) (OR 1.57, 95% CI, 1.14, 2.2) and diabetic foot t (OR 1.62,
95% CI 1.12, 2.40) were all significantly associated with the insulin therapy. Obese
and overweight patients were prescribed oral antidiabetic drugs. [metformin (OR
1.25, 95% CI 1.15, 1.35), sulfonylurea (OR 1.28, 95% CI 1.01, 1.61)]. CONCLUSIONS:
This study finding indicates that medication use was consistent with evidence
based practice guidelines in T2DM. There was, however, scope for improvement in
prescribing, especially in the T2DM patients with complications.
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OBJECTIVES: There is a growing interest in the use of electronic medical records
(EMRs) for clinical research. The study describes a collaborative research project
that uses an EMR database to explore the level of diabetic care in patients with type
2 diabetes in a primary care setting. METHODS: A retrospective study was con-
ducted using the GE Centricity electronic medical records (EMR) database of a pri-
mary care physicians group. Patients with type 2 diabetes were identified using
ICD-9 codes of 250.xx (January 1, 2004 toMarch 31, 2009). Patients 18 years of age,
with two or more visits with their respective physicians, and having an active
status in the database were selected. Demographic characteristics, clinical param-
eters (HbA1c, LDL, HDL)medication use, and number of office visitswere identified.
Data was extracted using Microsoft SQL and descriptive statistical analyses were
conducted using SPSS version 18.0. RESULTS: The study identified 4,598 patients
(mean age: 67 12.9 years and males: 51.8%) with type 2 diabetes. A total of 24,590
office visits were recorded with a mean of 14.1 visits and 127 days between visits.
3,100 (61.3%) patients had HbA1c levels  7; 1,473 (29.1%) patients had levels be-
tween 7-9; and 484 (9.6%) patients had levels  9. 3,970 (59.2%) patients had LDL
below 100 mg/dL and 2,737 (40.8%) had LDL greater than 100 mg/dL. Mean number
of active medications were 2.34 and diabetes medications were 1.94. Combination
drugs were used the most compared with amino acid derivatives and amylin
analogs. CONCLUSIONS: The collaborative research project has been established
between clinicians and researchers, a baseline data extraction has been developed
and now further studywill be necessary to prove that specific interventions in high
risk patients, i.e. HbA1c  9, can ultimately improve care.
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OBJECTIVES: A central Texas health plan implemented a pharmacist-led diabetes
medication management program (MMP) offering co-pay waivers for diabetes re-
lated medications and supplies. Medication adherence, diabetic control and
healthcare costs were compared between patients enrolled in the MMP and
matched control patients.METHODS: Patientswere enrolled in theMMP if they had
baseline A1C levels  7.5% and three years of continuous enrollment throughout
the study period (“rolling” enrollment from 7/06-12/08). The enrollees and controls
were matched 1:1 by age, gender, baseline A1C, and Charlson comorbidity index
(CCI). A1C and adherence (Medication Possession Ratio (MPR)) were measured one
year before and two years after implementation. A difference in difference analysis
used paired t-tests to compare changes in MPR and A1C. Healthcare costs were
analyzed by year, group, types of service, diabetes-related and all-cause claims.
RESULTS: 144 patientswere enrolled in theMMP for at least two years. AverageA1C
decreased by 0.8 in controls and 1.5 inMMPpatients; the difference between groups
was statistically significant (P0.01). While both groups declined in MPR for oral
antidiabetic drugs (MMP:10% vs. Control:19%), the difference between the groups
was statistically significant (P0.009). After two years, the average permember per
month (PMPM) costs increased by 16% and 36% inMMP and control groups, respec-
tively. The increasewasmainly attributable to growth in diabetes-related drug and
outpatient claims in the MMP group. Inpatient costs appeared to be the greatest
difference between the two groups, decreasing by 38% in the MMP group and in-
creasing by 159% in the control group.CONCLUSIONS:When compared tomatched
control patients, the MMP showed improved patient clinical and adherence mea-
sures. Although two-year PMPM costs increased, the significant difference in inpa-
tient costs indicates a potential for longterm savings.
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OBJECTIVES: Assess the clinical and economic impact of pharmacist education,
monitoring, andmanagement of patients with diabetes mellitus (DM) enrolled in a
free clinic that serves a rural indigent population.METHODS:Data from77 patients
continuously enrolled in a newly established pharmacist service were analyzed.
Patients were18 years of age, qualified for free care on the basis of income and/or
insurance status, and had a diagnosis of DM upon entry. Under a collaborative
agreement, pharmacists educated patients on DM, counseled patients on lifestyle
modifications, assessed appropriateness of drug therapy, and managed drug ther-
apy for DM and associated comorbid conditions. Clinical impact was measured by
changes from baseline in hemoglobin A1c (A1c) levels, blood pressure, and lipid
levels over a 12 month period. Using cost estimates published in the literature,
economic impact was calculated based upon expected savings per 1% decrease in
A1c levels. RESULTS: Mean A1c levels were 10.6% at baseline (SD 2.5 %). At one
year, A1c levels decreased an average of 2.3% (P0.001), and 44.2% of patients had
an A1c 7%. A significant number of patients achieved A1c goal by one year
(P0.0001). Significant decreases in mean values were also noted for systolic blood
pressure (SBP) (P0.02), LDL-cholesterol (P 0.001), and triglycerides (P 0.001). A
significant number of patients reached a SBP goal 130 mmHg (P0.033), LDL-
cholesterol 100 mg/dL (P0.0001), or triglycerides 150 mg/dL (P0.0001). Based
on an expected savings of $1,118 per 1% decrease in HbA1C levels, the average
savings per patient was $2,600, for a total savings potential of $167,364.
CONCLUSIONS: Pharmacist management of patients with DM has the potential to
significantly impact clinical outcomes and improve costs of care for patients in
underserved rural areas.
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OBJECTIVES:Average adherence to therapy in patients with diabetes is only 67.5%.
This study aims to evaluate the impact of a pharmacist-based diabetes manage-
ment program on improving medication adherence among diabetic patients.
METHODS: Data collected during a collaborative program in which trained phar-
macists provided diabetes management including medication, education and diet
and lifestyle modification counseling to diabetic patients was obtained. Medica-
tions dispensed before (in 2007) and during (in 2008) the intervention was recorded
for the patients receiving the intervention and controls (matched on age 5 years,
HbA1C0.1%, gender, and baseline cholesterol levels) as part of this retrospective,
longitudinal study. Patientswith two ormore visits at the participating pharmacies
were included in the study. Medication Possession Ratios (MPRs) were calculated
for every patient. Analysis involving descriptive statistics and t-tests were per-
formed using SAS version 9.2. RESULTS: A total of 135 cases and 243 controls were
included in the study of which 53.3% (n72) and 50.78% (n122) were females,
respectively. The mean age (SD) of cases and controls was similar 48.6 (11.4) and
47.4 (13.1) years, respectively. The mean MPR(SD) of cases improved from 3.41(3.7)
in 2007 to 5.12(10.7) in 2008 (p0.0902). The MPR(SD) for controls, reduced from
2.96(2.9) in 2007 to 2.16(6.8) in 2008. When the changes in MPR(SD) of every individ-
ual were compared cases showed greater change of 1.75(1.4) on an average as
compared to 0.015(1.8) for controls(p0.0907). Although not significant (p0.083),
the percentage of cases that were non-adherent reduced by around 50% from 8.9%
in 2007 to 4.4% in 2008. CONCLUSIONS: Adherence to medication in diabetic pa-
tients may be improved thorough a planned pharmacists-based disease manage-
ment program. Further, longitudinal data may be needed to conclusively indicate
the impact of pharmacists based intervention.
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OBJECTIVES: We assessed the impact of the use of a generic substitute of rosigli-
tazone (an anti-diabetic drug) on patient outcomes and treatment costs.
METHODS: From the Maccabi Healthcare Services computerized databases we
identified three groups of diabetic patients: 1. Patients who purchased the branded
medication Avandia® and switched entirely to its’ generic substitute Rossini®
(same number of packages and dosage; the intervention group; N1,632), 2. Pa-
tients who switched to Rossini® partially (different number of packages and/or
different dosage; the control group; N440), and 3. Patients who did not switch to
Rossini® at all (N897). For each patient we retrospectively obtained and compared
the following parameters 6-months prior to, and 6-months following the switch:
HbA1c levels, number of medication packages purchased, number of physician
visits, hospital and emergency room admissions, and pharmaceutical costs.
RESULTS: In patients who switched entirely from Avandia® to Rossini® we found a
45% decrease in treatment costs (p0.001), as compared with a 29% decrease in
costs in the control group that continued treatment with Avandia® (p0.001) and
37% decrease (p0.001) in the control group that partially switched to Rossini® (in
the control groups there was a decline in the number of packages that were pur-
chased after the switch). In the intervention group, we observed a reduction of 0.1%
in HbA1c levels [from 7.61.3% to 7.51.4% (p0.001)] in comparison to a non-
significant difference in the two other groups [from 7.91.5% to 7.91.6% (p0.198)
and from 7.81.4% to 7.71.7% (p0.261), respectively].We found a decrease in the
number of physician visits, and no difference in the number of hospitalization days
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